Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Baxter International Inc (BAX) vs Huntington Ingalls Industries Inc (HII) Price & Performance

Baxter International IncTrade
Huntington Ingalls Industries IncTrade

Price performance (Past 24H)

Key statistics

Baxter International Inc vs Huntington Ingalls Industries Inc — how do they compare? Baxter International Inc trades at $27.21 (market cap $14.27B), while Huntington Ingalls Industries Inc trades at $328.1 (market cap $12.92B). The key difference: Baxter International Inc and Huntington Ingalls Industries Inc are close in size by market cap, and Huntington Ingalls Industries Inc pays the higher dividend (1.68%). Which is the better fit depends on your goals.

BAXHII
Market Cap
$14.27B$12.92B
Sector
HealthTechnology
52-Week High
$28.35$453.73
52-Week Low
$15.80$265.40
Enterprise Value
$21.79B$15.84B
Dividend Yield
0.14%1.68%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Baxter International Inc

Baxter International (BAX) trades at $27.22, down 2.02% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.56, beating expectations of $0.3665, and raised full-year guidance. Despite negative net income margins and high P/E of 87.85, cash flow trends improved with 2026 net cash flow projected at $468 million. Recent news highlights a 7.4% surge on August 3, 2026, following positive quarterly results and a cash tender offer announcement.

The outlook is cautiously optimistic due to earnings momentum and raised guidance, but high valuation and persistent negative profitability pose risks. Analyst consensus is mixed with 41.67% buy ratings, a $25.43 price target, and institutional activity showing volatility. Key risks include margin pressures and debt levels, though operational improvements may support recovery.

Huntington Ingalls Industries Inc

HII trades at $328.43, down 0.72% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $5.27 versus $3.79 expected, and revenue growth of 10.9%. Recent news includes a $2.2 billion contract award for surveillance and intelligence capabilities, enhancing its defense portfolio. Valuation ratios show a P/E of 19.53 and P/S of 0.98, indicating reasonable pricing relative to earnings and sales.

Outlook is positive due to contract wins and operational improvements, but risks include political headwinds and execution challenges. Analyst consensus price target is $359.67, suggesting 9.5% upside. Investment opportunity lies in margin expansion from submarine contracts, while monitoring defense budget volatility is key.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Baxter International Inc

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.

Read more on BAX

About Huntington Ingalls Industries Inc

Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.

Read more on HII